CTI Biopharma Corp.'s pacritinib hit the primary endpoint in the first phase III study evaluating the next-generation JAK2/FLT3 multikinase inhibitor in myelofibrosis patients, with top-line data also showing benefit in a subset currently not helped by marketed JAK2 inhibitor Jakafi (ruxolitinib), findings that could provide crucial differentiation in the marketplace.